Table 2. Recipient postoperative status, complications, and immunosuppressive therapya.
| Basiliximab (n = 78) | Steroid (n = 100) | P-value | |||
| Follow-up time (month) | |||||
| Median (IQR) | 37.2 (8.7, 52.6) | 19.5 (4.1, 83.3) | 0.819† | ||
| Mean ± SD | 33.4±23.8 | 39.9±40.1 | 0.180§ | ||
| Mortality, perioperative period | 4 (5.1) | 11 (11.0) | 0.162‡ | ||
| Mortality | 34 (43.6) | 42 (42.0) | 0.832‡ | ||
| Cause of death | |||||
| Graft failure | 1 (2.9) | 1 (2.4) | 0.591‡ | ||
| Hemorrhage | 3 (8.8) | 1 (2.4) | |||
| Multi-organ failure | 22 (64.7) | 30 (71.4) | |||
| Respiratory complication | 1 (2.9) | 1 (2.4) | |||
| Died after re-transplantation | 1 (2.9) | 4 (9.5) | |||
| Recurrent disease | 6 (17.7) | 4 (9.5) | |||
| Other | 0 (0.0) | 1 (2.4) | |||
| HBV recurrence | n = 72 | 8 (11.1) | n = 92 | 4 (4.4) | 0.099‡ |
| De novo HBV infection | n = 6 | 2 (33.3) | n = 8 | 2 (25.0) | 1.000¶ |
| De novo diabetes | n = 75 | 29 (38.7) | n = 89 | 81 (91.0) | <0.0001‡ |
| Long-term de novo diabetes | n = 75 | 3 (4.0) | n = 89 | 27 (30.3) | <0.0001‡ |
| De novo hypertension | n = 72 | 4 (5.6) | n = 94 | 5 (5.3) | 1.000¶ |
| De novo hyperlipidemia | n = 75 | 3 (4.0) | 1 (1.0) | 0.315¶ | |
| Pleural effusion | 63 (80.8) | 54 (54.0) | 0.0002‡ | ||
| Postoperative infection | 33 (42.3) | 23 (23.0) | 0.006‡ | ||
| Biliary complication | 6 (7.7) | 5 (5.0) | 0.538¶ | ||
| Renal failure | 1 (1.3) | 7 (7.0) | 0.081¶ | ||
| Pulmonary edema | 2 (2.6) | 5 (5.0) | 0.469 | ||
| Intra-abdominal bleeding | 7 (9.0) | 5 (5.0) | 0.294‡ | ||
| Intra-abdominal collection/abscess | 6 (7.7) | 1 (1.0) | 0.045¶ | ||
| Vascular complication | 2 (2.6) | 3 (3.0) | 1.000¶ | ||
| CMVpp65 antigenemia | 0 (0.0) | 1 (1.0) | 1.000¶ | ||
| Primary graft nonfunction | 0 (0.0) | 1 (1.0) | 1.000¶ | ||
| Chronic rejection | 0 (0.0) | 0 (0.0) | NA | ||
| GVHD | 0 (0.0) | 0 (0.0) | NA | ||
| PTLD | 0 (0.0) | 0 (0.0) | NA | ||
| Postoperative immunosuppressive therapy b | |||||
| Recipient alive at end of study | 44 (56.4) | 58 (58.0) | |||
| Maintenance immunosuppressant | |||||
| Tacrolimus | 42 (95.5) | 54 (93.1) | 0.697¶ | ||
| MMF | 40 (90.9) | 58 (100.0) | 0.032¶ | ||
| Sirolimus | 0 (0.0) | 5 (8.6) | 0.068¶ | ||
| Immunosuppression protocol, n (%) | |||||
| Tacrolimus+MMF+sirolimus | 0 (0.0) | 5 (8.6) | 0.017¶ | ||
| Tacrolimus+MMF | 38 (86.4) | 49 (84.5) | |||
| Tacrolimus only | 4 (9.1) | 0 (0.0) | |||
| MMF only | 2 (4.6) | 4 (6.9) | |||
Data are presented as number (percentage), median (IRQ), or mean ± standard deviation.
a
The number of patients for the basiliximab and steroid groups are 78 and 100, respectively unless indicated otherwise.
b
The number of patients for the basiliximab and steroid groups are 44 and 58, respectively.
†
Wilcoxon rank sum test;
‡
Chi-square test;
¶
Fisher’s exact test;
§
independent t-test.
CMV = cytomegalovirus; GVHD = graft versus host disease; MMF = mycophenolate mofetil; NA = not available; PTLD = post-transplant lymphoproliferative disorder.